Gene-Disorder Association · Article
First reported
1950
Supporting publications
1
Approved treatment annotated
Association Review
In brief
The association between CASP3 (Caspase 3) and Esophageal Cancer is reported, supported by a single source.
Sources
1
Clinical variants
0
Symptoms
17
Compounds
1
Trials
150of 3,366 via CASP3 compounds
Publications
1
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Esophageal Cancer
The disorder
40 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Phenotype
Clinical features
1 clinical feature
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access
06
Genomic context
Regulatory context
1 regulatory element
GeneHancer regulatory elements for the pair, with coordinates, score, element type and supporting literature.
Request access
07
Interventions
Therapeutics
1 compound or drug
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
08
Human studies
Clinical trials
3,366 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
1 publication
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
10
Provenance
References & sources
10 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access